Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
EditorialEditorial

Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF

Hongquan Wang, Shuang Wu, Yan Wang and Bo Tang
Cancer Biology & Medicine July 2022, 19 (7) 945-947; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0299
Hongquan Wang
1Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuang Wu
1Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Wang
1Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Tang
1Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bo Tang
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

References

  1. 1.↵
    1. Lambert A,
    2. Conroy T,
    3. Ducreux M.
    Future directions in drug development in pancreatic cancer. Semin Oncol. 2021; 48: 47–56.
    OpenUrl
  2. 2.↵
    1. Easwaran H,
    2. Tsai HC,
    3. Baylin SB.
    Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014; 54: 716–27.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Lodestijn SC,
    2. van Neerven SM,
    3. Vermeulen L,
    4. Bijlsma MF.
    Stem cells in the exocrine pancreas during homeostasis, injury, and cancer. Cancers (Basel). 2021; 13: 3295.
    OpenUrl
  4. 4.↵
    1. Bayik D,
    2. Lathia JD.
    Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer. 2021; 21: 526–36.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Oshimori N,
    2. Guo Y,
    3. Taniguchi S.
    An emerging role for cellular crosstalk in the cancer stem cell niche. J Pathol. 2021; 254: 384–94.
    OpenUrl
  6. 6.↵
    1. Chan TS,
    2. Shaked Y,
    3. Tsai KK.
    Targeting the interplay between cancer fibroblasts, mesenchymal stem cells, and cancer stem cells in desmoplastic cancers. Front Oncol. 2019; 9: 688.
    OpenUrlPubMed
  7. 7.↵
    1. Sagara A,
    2. Nakata K,
    3. Yamashita T,
    4. Guan W,
    5. Zhong P,
    6. Matsumoto S, et al.
    New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth. Pancreatology. 2021 S1424-3903(21)00141-1: Online ahead of print doi:10.1016/j.pan.2021.04.002.
    OpenUrlCrossRef
  8. 8.
    1. Dalin S,
    2. Sullivan MR,
    3. Lau AN,
    4. Grauman-Boss B,
    5. Mueller HS,
    6. Kreidl E, et al.
    Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance. Cancer Res. 2019; 79: 5723–33.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Wu Y,
    2. Zhang C,
    3. Jiang K,
    4. Werner J,
    5. Bazhin AV,
    6. D’Haese JG.
    The role of stellate cells in pancreatic ductal adenocarcinoma: targeting perspectives. Front Oncol. 2020; 10: 621937.
  10. 10.↵
    1. Chen X,
    2. Zhang Y,
    3. Qian W,
    4. Han L,
    5. Li W,
    6. Duan W, et al.
    Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions. iScience. 2021; 24: 103400.
  11. 11.↵
    1. Zhou T,
    2. Liu J,
    3. Xie Y,
    4. Yuan S,
    5. Guo Y,
    6. Bai W, et al.
    ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. Gut. 2022; 71: 357–71.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Jha NN,
    2. Kumar R,
    3. Panigrahi R,
    4. Navalkar A,
    5. Ghosh D,
    6. Sahay S, et al.
    Comparison of α-Synuclein fibril inhibition by four different amyloid inhibitors. ACS Chem Neurosci. 2017; 8: 2722–33.
    OpenUrl
  13. 13.↵
    1. Albino D,
    2. Longoni N,
    3. Curti L,
    4. Mello-Grand M,
    5. Pinton S,
    6. Civenni G, et al.
    ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features. Cancer Res. 2012; 72: 2889–900.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Li J,
    2. Yang J,
    3. Hua L,
    4. Wang R,
    5. Li H,
    6. Zhang C, et al.
    Ese-3 contributes to colon cancer progression by downregulating EHD2 and transactivating INPP4B. Am J Cancer Res. 2021; 11: 92–107.
    OpenUrl
  15. 15.↵
    1. Lyu Z,
    2. Ma M,
    3. Xu Y,
    4. Wang X,
    5. Zhu Y,
    6. Ren W, et al.
    Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma. Int J Clin Oncol. 2020; 25: 1334–45.
    OpenUrl
  16. 16.↵
    1. Zhao T,
    2. Jiang W,
    3. Wang X,
    4. Wang H,
    5. Zheng C,
    6. Li Y, et al.
    ESE3 Inhibits pancreatic cancer metastasis by upregulating E-cadherin. Cancer Res. 2017; 77: 874–85.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Liu J,
    2. Jiang W,
    3. Zhao K,
    4. Wang H,
    5. Zhou T,
    6. Bai W, et al.
    Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. J Exp Med. 2019; 216: 656–73.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Cancer Biology & Medicine: 19 (7)
Cancer Biology & Medicine
Vol. 19, Issue 7
15 Jul 2022
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
Hongquan Wang, Shuang Wu, Yan Wang, Bo Tang
Cancer Biology & Medicine Jul 2022, 19 (7) 945-947; DOI: 10.20892/j.issn.2095-3941.2022.0299

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
Hongquan Wang, Shuang Wu, Yan Wang, Bo Tang
Cancer Biology & Medicine Jul 2022, 19 (7) 945-947; DOI: 10.20892/j.issn.2095-3941.2022.0299
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Grant support
    • Conflict of interest statement
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Optimization of regional nodal irradiation in the era of sentinel lymph node biopsy
  • Mission of the National Cancer Center Hospital in Japan to promote clinical trials for precision medicine
  • Inconsistent radiotherapy effects between primary tumors and axillary lymph nodes
Show more Editorial

Similar Articles

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2023 Cancer Biology & Medicine

Powered by HighWire